Fundraising Fox

ExSight Ventures

Venture capital

Pre-Seed–Series B · 4 people tracked

Fox Verdict
Sign up to see your fit

Investment thesis

ExSight Ventures invests in early-stage companies developing breakthrough technologies to aid, diagnose, and treat people affected by vision diseases. The firm leverages deep ophthalmology domain expertise—led by two retinal surgeons—as an advantage over generalist investors, treating its focused specialization as a form of validation for a company's technology. It emphasizes capital efficiency, investing predominantly in technology development at the pre-seed through Series B stages. The firm argues that diversification is best achieved across focused managers rather than across holdings, and points to macro trends such as an aging population, rising diabetes, and a growing global middle class as drivers of demand for eye care innovation.

Source: firm website, verified Aug 3, 2026.

Stage
Pre-Seed–Series B
Instruments
Equity
Tracked investments
23

Team · 4 people

from the firm's website

What they invest in

from 6 of 23 portfolio companies

Biotech ×5Medical Devices ×2Healthtech ×1

HQs:United States×6

Investments · 23 tracked

founders shown can be your intro path
2Ctechcorp2ctechcorp.com
Ajoajo.com
DTx Pharmadtxpharma.comin𝕏

Novartis is a pharmaceutical company with a history spanning 250 years of scientific innovation.

BiotechSan Diego, US

Arthur T Suckow(Executive Officer)

ELIOS Vision

Implant-free, minimally invasive glaucoma surgery (MIGS) creating microscopic channels in the eye to lower intraocular pressure.

Eliosvisioneliosvision.comin𝕏
Envision Diagnostics

Reinventing the eye exam with binocular OCT-based diagnostic technology.

Googleyoutu.be
Horizonsurgicalsystemshorizonsurgicalsystems.comin
LensGenlensgen.com

Juvene Curvature Changing develops a fluid-optic intraocular lens designed to mimic the natural human lens and correct vision in patients with cataracts and presbyopia.

HealthtechMedical DevicesIrvine, US

Akiteru Furukawa(Director)Michael Colaco(Director)Ramgopal Rao(Executive Officer, Director)

Lwwlww.com
Novai

British biotech startup with an AI-supported retinal biomarker for glaucoma and AMD clinical trials.

Oisois.netin𝕏
ONL Therapeuticsonltherapeutics.com

BiotechAnn Arbor, US

David Zacks(Executive Officer)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)Loic K Couraud(Director)William K Brinkerhoff(Director)Mark K Hooper(Director)

Quraqura.biz
Re-vanarevanatx.com
RetroSense Therapeuticsacquired by Allergan

First-in-class optogenetic therapy for retinal diseases; acquired by Allergan.

BiotechAnn Arbor, US

Terry Cross(Director)Cam Gallagher(Director)Sean Ainsworth(Executive Officer, Director)George Lasezkay(Director)Kenneth Kousky(Director)

Springerspringer.comin𝕏
Trefoil Therapeuticstrefoiltherapeutics.comin

BiotechSan Diego, US

Ralph Bradshaw(Director)Christy Shaffer(Director)Schalon Newton(Executive Officer)David Eveleth(Executive Officer, Director)

Valitor

Leveraging a multi-valent biopolymer to engineer medicines that overcome limitations of established drug targets.

Berkeley, US

Carole H Bellis(Executive Officer)Drew M Lanza(Director)Kevin E Healy(Director)Walter M Moos(Director)Jackson M Wesley(Executive Officer, Director)

Valitorvalitorbio.comin

Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration.

BiotechMedical Devices

Wesley Jackson(President, Chief Scientific Officer & Member of the Board)Gregory D. Kunst(Chief Executive Officer)

Frequently asked questions

What stage does ExSight Ventures invest at?
ExSight Ventures invests at the Pre-Seed, Seed, Series A, Series B stages.
What sectors does ExSight Ventures focus on?
ExSight Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Similar investors

Featured in lists